Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 6/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6925573 | 0.87 | KDM4E (0.43) | HTR2CKDM4EHTR2BHTR2AEPHX2 | |
| SCHEMBL6923415 | 0.82 | HTR2C (0.44) | HTR2CKDM4EHTR2BHTR2AEPHX2 | |
| SCHEMBL7379014 | 0.81 | HTR2C (0.48) | HTR2CKDM4EHTR2BHTR2AEPHX2 | |
| SCHEMBL6924610 | 0.79 | ALDH1A1 (0.61) | EPHX2ALDH1A1 | |
| SCHEMBL6926479 | 0.79 | F2 (0.60) | ALDH1A1 | |
| SCHEMBL6926419 | 0.76 | MEN1 (0.48) | KDM4EALDH1A1SMN1; SMN2MDM2 | |
| SCHEMBL6924964 | 0.74 | HTR2C (0.46) | HTR2CKDM4EHTR2BHTR2AGID4 | |
| SCHEMBL6925564 | 0.73 | EGFR (0.45) | KDM4EALDH1A1DDR1SCN9AMDM2 | |
| SCHEMBL6925098 | 0.73 | HTR2C (0.46) | HTR2CKDM4EHTR2BHTR2AGID4 | |
| SCHEMBL17231940 | 0.73 | HTR2C (0.58) | HTR2CKDM4EHTR2BHTR2AGID4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515011-B2 | Anticoagulants | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| US-20020119992-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002050056-A1 | BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119992-A1 | Thrombin inhibitors | SERPINC1, F2, TFPI | HTR2C 524/4885KDM4E 3420/4885HTR2B 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.